About Bioxcel Therapeutics
BioXcel Therapeutics uses its proprietary drug re-innovation platform to identify, develop, and commercialize CNS treatments including BXCL501 sublingual dexmedetomidine.
📍 Location & Offices
📋 Request a Quote
Send your requirements directly to Bioxcel Therapeutics. Response typically within 48 hours.
Company Info
TypePublic
StockBTAI (NASDAQ)
Founded2017
Employees180
Revenue$38M
HQNew Haven, USA
